Correction to: SIRT3 activation protects from nabumetone-induced mitochondrial toxicity in adult human cardiomyocytes Authors: Yafei Huang, Hong Liu, Chao Tong, Zhimin Wang, Miaomiao Xu, Mengqi Dong, Rongjia Rao, Xianqiang Wang, Wei Feng, Zhan Hu, Fei Xu, Wei Zhao, Li Wang, Shengshou Hu, Bingying Zhou Published: 2026 Correction to: Cellular and Molecular Life Sciences (2026) 83:171 10.1007/s00018-026-06142-z In this article, the legends of figure 4 and 5 has been incorrectly published. For completeness and transparency, the correct figure legends have been attached below with the respective figures. Incorrect Figure with Legend (FSV: insert it from published article with the legend) Correct Figure with legend (FSV: insert the image of 4) Fig. 4. The PGE2-EP4 pathway is critical to mitochondrial dysfunction in human cardiomyocytes. (A) Effect of Nab treatment on prostaglandin (PGE2, PGD2, TBXA2, PGI2, PGF2α) production in hPCMs (n = 3 patients). (B-C) Pretreatment with PGE2 for 3 h attenuates the effects of Nab on mitochondrial membrane potential (MMP) and mitochondrial permeability transition pore (mPTP) opening in hPCMs (n = 5 patients). (D-F) Pretreatment with EP3 and EP4 receptor agonists for 3 h modulates MMP, mPTP opening, and ROS production in hPCMs (MMP, mPTP: n = 3 patients; ROS: n = 4 patients). (G) Pretreatment with EP3 and EP4 receptor antagonists for 3 h reverses the effects of Nab on MMP, mPTP opening, and ROS production in hPCMs (MMP, mPTP: n = 3 patients; ROS: n = 4 patients). (H-I) Pretreatment with the EP4 agonist compound 31 for 3 h attenuates the effects of Nab on oxygen consumption rate (OCR) in hPCMs. (H) Representative OCR traces. (I) Quantification of OCR (n = 6 patients). (J-L) Pretreatment with the EP4 agonist for 3 h attenuates the effects of Nab on mitochondrial complex activity in hPCMs. (J) Representative OCR traces. (K, L) Quantification of mitochondrial complex activity (n = 4 patients). (M-O) Pretreatment with the EP4 agonist for 3 h attenuates the effects of Nab on electrophysiological action potentials in hPCMs. (M) Representative action potential (AP) traces. (N, O) Quantification of action potential parameters (n = 3 patients). Data are presented as mean ± SEM. Statistical significance was determined by Student’s t-test for two groups and repeated measures one-way ANOVA followed by Dunn’s post-hoc test for three or more groups. *p < 0.05, **p < 0.01 Incorrect Figure with Legend (FSV: insert it from published article with the legend) Correct Figure with legend (FSV: insert the image of 5) Fig. 5. SIRT3 activator honokiol ameliorates nabumetone-induced mitochondrial and cellular dysfunction in hPCMs. (A-B) Expression of mitochondrial complex II and III protein subunits SDHA, SDHB, and MT-CYB. (A) Representative immunoblot. (B) Quantitative analysis (n = 3 patients). (C) SIRT3 mRNA expression levels (n = 3 patients). (D) Effect of nabumetone (Nab, 10 µM) on SIRT3 protein expression in hPCMs (48 h). Representative immunoblot (left) and quantitative analysis (right). GAPDH was used as a loading control (n = 3 patients). (E) Effect of Nab on SIRT3 activity, as assessed using a SIRT3 activity assay kit (n = 3 patients). (F) Effect of 3 h pretreatment with the SIRT3 activator honokiol on mitochondrial membrane potential (MMP) in hPCMs treated with Nab (n = 5 patients). (G) Effect of 3 h pretreatment with honokiol on oxygen consumption rate (OCR) in hPCMs treated with Nab. (left) Representative OCR traces. (right) Quantification of OCR (n = 3 patients). (H) Effect of 3 h pretreatment with honokiol on mitochondrial complex activity in hPCMs treated with Nab. (left) Representative Seahorse traces. (right) Quantification of mitochondrial complex activity (n = 3 patients). (I) Effect of 3 h pretreatment with honokiol on electrophysiological action potentials in hPCMs treated with Nab. (left) Representative action potential (AP) traces. (right) Quantification of action potential parameters (n = 4 patients). Data are presented as mean ± SEM. Statistical significance was determined by Student’s t-test for two groups and repeated measures one-way ANOVA followed by Dunn’s post-hoc test for three or more groups. *p < 0.05, **p < 0.01 The original article has been corrected.